Sage Therapeutics Inc. (NASDAQ:SAGE) was up 3.4% during mid-day trading on Friday . The company traded as high as $44.97 and last traded at $44.86, with a volume of 208,487 shares changing hands. The stock had previously closed at $43.39.

A number of equities research analysts recently issued reports on SAGE shares. William Blair restated a “buy” rating on shares of Sage Therapeutics in a report on Sunday, March 27th. Goldman Sachs Group Inc. started coverage on shares of Sage Therapeutics in a report on Wednesday, March 30th. They issued a “neutral” rating and a $83.00 target price for the company. Leerink Swann restated a “buy” rating and issued a $66.00 target price on shares of Sage Therapeutics in a report on Friday, April 8th. Zacks Investment Research cut shares of Sage Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, April 27th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $110.00 price target on shares of Sage Therapeutics in a research report on Sunday, May 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Sage Therapeutics currently has a consensus rating of “Buy” and an average target price of $66.18.

The stock’s market cap is $1.42 billion. The company has a 50-day moving average price of $33.88 and a 200-day moving average price of $34.59.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.01. Equities analysts anticipate that Sage Therapeutics Inc. will post ($4.34) EPS for the current year.

In other news, CFO Kimi Iguchi sold 5,000 shares of the company’s stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $49.55, for a total value of $247,750.00. Following the transaction, the chief financial officer now owns 83,739 shares in the company, valued at approximately $4,149,267.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Kevin P. Starr sold 850,000 shares of the company’s stock in a transaction dated Monday, May 16th. The shares were sold at an average price of $31.25, for a total value of $26,562,500.00. Following the completion of the transaction, the director now owns 65,227 shares in the company, valued at approximately $2,038,343.75. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. Jennison Associates LLC acquired a new position in shares of Sage Therapeutics during the fourth quarter worth $14,875,000. Marshall Wace LLP acquired a new position in shares of Sage Therapeutics during the fourth quarter worth $1,870,000. BB Biotech AG acquired a new position in shares of Sage Therapeutics during the fourth quarter worth $41,315,000. ProShare Advisors LLC increased its position in shares of Sage Therapeutics by 8.2% in the fourth quarter. ProShare Advisors LLC now owns 25,219 shares of the biopharmaceutical company’s stock worth $1,470,000 after buying an additional 1,919 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Sage Therapeutics by 1.6% in the fourth quarter. California State Teachers Retirement System now owns 25,578 shares of the biopharmaceutical company’s stock worth $1,491,000 after buying an additional 400 shares in the last quarter.

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Company’s lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.